Christina Miteff

Christina Miteff

Auto-generated profile, based on publicly available information

Christina Miteff

Department of Neurology, John Hunter Children’s Hospital, Newcastle, New South Wales, Australia (C.M., F.M., R.L.S., G.M.S.).

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
KBKartik D. Bhatia
Kartik D. Bhatia
VJVvenkata Pavan Joga
Vvenkata Pavan Joga
PMPrakash Muthusami
Prakash Muthusami
CPCarmen Parra-Farinas
Carmen Parra-Farinas
EPElizabeth Pulcine
Elizabeth Pulcine
PSPeter Sporns
Peter Sporns
Background and ObjectivesNeurologic outcomes after pediatric large vessel occlusion (LVO) stroke are poor. In the absence of a pediatric randomized clinical trial, cohort and registry studies have ...

1 October 2026 in Stroke
Verified
Journal Article
Closed access
RBRomain C. Briest
Romain C. Briest
KBKartik D. Bhatia
Kartik D. Bhatia
CMChristina Miteff
Christina Miteff
ACAndrew Cheung
Andrew Cheung
JAJayne Antony
Jayne Antony
PAP. Ian Andrews
P. Ian Andrews
BACKGROUND: Thrombolysis is infrequently delivered to children with acute ischemic strokes (AIS). We explored potential eligibility for treatment with tPA (tissue-type plasminogen activator) for pediatric AIS. METHODS: This retrospective, multicenter, observational, cohort study reviewed children aged 29 days to 17 years with symptomatic AIS identified via Children’s Hospital Westmead, John Hunter Children’s Hospital, and Sydney Children’s Hospital between January 1, 2010, and December 31, 2019. Medical records were examined to evaluate eligibility for treatment with tPA based on established multinational and the 2026 American Heart Association guidelines, reasons for exclusion beyond delay to diagnosis, and long-term outcomes as pediatric modified Rankin Scale scores. We also explored additional exclusions and outcomes among children with small-vessel AIS and AIS in the context of brain tumors, who are currently excluded from tPA. RESULTS: A total of 135 patients with 139 symptomatic AIS were identified—median age, 6 years; 36% female patients; 73% presented via emergency departments; mean follow-up, 43 months; 12% deaths. Irrespective of delay to diagnosis, only 26 of 139 (19%) AIS were potentially eligible for treatment with tPA. Among patients potentially eligible for tPA, acute neuroimaging revealed large-vessel occlusions, unilateral focal cerebral arteriopathy, or extracranial dissections. Thirteen of 26 (50%) had nondisabled outcomes without tPA treatment. One hundred thirteen of 139 (81%) AIS were ineligible for treatment with tPA, irrespective of delay to diagnosis. All deaths occurred among patients excluded from tPA, predominantly related to underlying disorders. Fifty-four small-vessel AIS accounted for 39% of AIS. Eighteen (33%) had no additional ineligibilities to thrombolysis, among whom 10 had nondisabled outcomes without tPA. CONCLUSIONS: Based on current recommendations, 19% of symptomatic childhood AIS were potentially eligible for treatment with tPA, irrespective of delay to diagnosis. Selected patients with small-vessel AIS may offer an opportunity to extend the role of tPA. These observations may be relevant for optimizing pediatric stroke management strategies.